The ABCG8 polymorphism increases the risk of gallbladder cancer in the general population and gallstones in obese patients from Poland.

ABCG8 polymorphism cholesterol gallbladder genetic risk hepatobiliary tumours obesity

Journal

European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331

Informations de publication

Date de publication:
14 Apr 2024
Historique:
revised: 28 03 2024
received: 28 12 2023
accepted: 29 03 2024
medline: 15 4 2024
pubmed: 15 4 2024
entrez: 15 4 2024
Statut: aheadofprint

Résumé

Gallstone disease (GD) is common but remains asymptomatic in most cases. However, gallstones can lead to complications like choledocholithiasis or gallbladder cancer. In this study, we analyse the common genetic risk factor for GD, the p.D19H variant in the sterol transporter ABCG8, in Polish patients with gallstones and gallbladder cancer. Three adult cohorts were prospectively recruited: 65 patients with gallbladder cancer, 170 obese individuals scheduled for bariatric surgery and 72 patients who underwent endoscopic retrograde cholangiopancreatography due to recurrent choledocholithiasis. The control cohort consisted of 172 gallstone-free adults. The ABCG8 p.D19H (rs11887534) polymorphism was genotyped using TaqMan assays. The minor allele frequency (MAF) of the ABCG8 p.D19H polymorphism was significantly (p = .02) higher among cases with either gallstones or gallbladder cancer (MAF = 8.4%) as compared to controls (MAF = 4.0%). The highest frequency of the risk allele was detected in patients with gallbladder cancer (18.5%) and obese patients with GD (17.5%), followed by individuals with choledocholithiasis (13.9%). Notably, the p.19H variant was associated with an increased risk of developing gallbladder cancer (OR 2.76, 95% CI 1.16-6.54, p = .01) and an increased risk of GD in obese individuals scheduled for bariatric surgery (OR = 2.70, 95% CI 1.05-6.49, p = .03), but did not significantly affect the risk of choledocholithiasis. The ABCG8 p.D19H common risk variant increases the risk of developing gallbladder cancer in Central Europeans and enhances the risk of gallstones in the obese. Carriers of the p.D19H variant might benefit from personalized preventive strategies, particularly regarding gallbladder cancer.

Sections du résumé

BACKGROUND BACKGROUND
Gallstone disease (GD) is common but remains asymptomatic in most cases. However, gallstones can lead to complications like choledocholithiasis or gallbladder cancer. In this study, we analyse the common genetic risk factor for GD, the p.D19H variant in the sterol transporter ABCG8, in Polish patients with gallstones and gallbladder cancer.
METHODS METHODS
Three adult cohorts were prospectively recruited: 65 patients with gallbladder cancer, 170 obese individuals scheduled for bariatric surgery and 72 patients who underwent endoscopic retrograde cholangiopancreatography due to recurrent choledocholithiasis. The control cohort consisted of 172 gallstone-free adults. The ABCG8 p.D19H (rs11887534) polymorphism was genotyped using TaqMan assays.
RESULTS RESULTS
The minor allele frequency (MAF) of the ABCG8 p.D19H polymorphism was significantly (p = .02) higher among cases with either gallstones or gallbladder cancer (MAF = 8.4%) as compared to controls (MAF = 4.0%). The highest frequency of the risk allele was detected in patients with gallbladder cancer (18.5%) and obese patients with GD (17.5%), followed by individuals with choledocholithiasis (13.9%). Notably, the p.19H variant was associated with an increased risk of developing gallbladder cancer (OR 2.76, 95% CI 1.16-6.54, p = .01) and an increased risk of GD in obese individuals scheduled for bariatric surgery (OR = 2.70, 95% CI 1.05-6.49, p = .03), but did not significantly affect the risk of choledocholithiasis.
CONCLUSIONS CONCLUSIONS
The ABCG8 p.D19H common risk variant increases the risk of developing gallbladder cancer in Central Europeans and enhances the risk of gallstones in the obese. Carriers of the p.D19H variant might benefit from personalized preventive strategies, particularly regarding gallbladder cancer.

Identifiants

pubmed: 38616505
doi: 10.1111/eci.14213
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14213

Subventions

Organisme : DAAD Ostpartnerschaften
Organisme : Cost Action: CA22125 - Precision medicine in biliary tract cancer (Precision-BTC-Network)

Informations de copyright

© 2024 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

Références

Portincasa P, Di Ciaula A, Bonfrate L, Stella A, Garruti G, Lamont JT. Metabolic dysfunction‐associated gallstone disease: expecting more from critical care manifestations. Intern Emerg Med. 2023;18:1897‐1918. doi:10.1007/s11739-023-03355-z
Lammert F, Miquel JF. Gallstone disease: from genes to evidence‐based therapy. J Hepatol. 2008;48(suppl 1):S124‐S135. doi:10.1016/j.jhep.2008.01.012
Shabanzadeh DM, Sorensen LT, Jorgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2016;150(1):156‐167. e1. doi:10.1053/j.gastro.2015.09.002
Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg. 1993;165(4):399‐404. doi:10.1016/s0002-9610(05)80930-4
European Association for the Study of the Liver. EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146‐181. doi:10.1016/j.jhep.2016.03.005
Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230‐239. doi:10.1016/S0140-6736(06)69044-2
Roa I, Ibacache G, Roa J, Araya J, de Aretxabala X, Munoz S. Gallstones and gallbladder cancer‐volume and weight of gallstones are associated with gallbladder cancer: a case‐control study. J Surg Oncol. 2006;93(8):624‐628. doi:10.1002/jso.20528
Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024. doi:10.1038/nrdp.2016.24
Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones: genetics versus environment. Ann Surg. 2002;235(6):842‐849. doi:10.1097/00000658-200206000-00012
Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005;41(5):1138‐1143. doi:10.1002/hep.20654
Buch S, Schafmayer C, Völzke H, et al. A genome‐wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007;39(8):995‐999. doi:10.1038/ng2101
Srivastava A, Tulsyan S, Pandey SN, Choudhuri G, Mittal B. Single nucleotide polymorphism in the ABCG8 transporter gene is associated with gallbladder cancer susceptibility. Liver Int. 2009;29(6):831‐837. doi:10.1111/j.1478-3231.2008.01907.x
Xu HL, Cheng JR, Andreotti G, et al. Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population‐based case‐control study in Shanghai, China. Carcinogenesis. 2011;32(1):58‐62. doi:10.1093/carcin/bgq194
Stender S, Frikke‐Schmidt R, Nordestgaard BG, Tybjaerg‐Hansen A. Sterol transporter adenosine triphosphate‐binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. Hepatology. 2011;53(2):640‐648. doi:10.1002/hep.24046
Haal S, Guman MSS, Bruin S, et al. Risk factors for symptomatic gallstone disease and gallstone formation after bariatric surgery. Obes Surg. 2022;32(4):1270‐1278. doi:10.1007/s11695-022-05947-8
Ando T, Tsuyuguchi T, Okugawa T, et al. Risk factors for recurrent bile duct stones after endoscopic papillotomy. Gut. 2003;52(1):116‐121. doi:10.1136/gut.52.1.116
Konstantakis C, Triantos C, Theopistos V, et al. Recurrence of choledocholithiasis following endoscopic bile duct clearance: long term results and factors associated with recurrent bile duct stones. World J Gastrointest Endosc. 2017;9(1):26‐33. doi:10.4253/wjge.v9.i1.26
Kim DI, Kim MH, Lee SK, et al. Risk factors for recurrence of primary bile duct stones after endoscopic biliary sphincterotomy. Gastrointest Endosc. 2001;54(1):42‐48. doi:10.1067/mge.2001.115335
Von Schönfels W, Buch S, Wolk M, et al. Recurrence of gallstones after cholecystectomy is associated with ABCG5/8 genotype. J Gastroenterol. 2013;48(3):391‐396. doi:10.1007/s00535-012-0639-3
Sun H, Warren J, Yip J, et al. Factors influencing gallstone formation: a review of the literature. Biomolecules. 2022;12(4):550. doi:10.3390/biom12040550
Sturm N, Schuhbaur JS, Hüttner F, Perkhofer L, Ettrich TJ. Gallbladder cancer: current multimodality treatment concepts and future directions. Cancers. 2022;14(22):5580. doi:10.3390/cancers14225580
Roa JC, Garcia P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69. doi:10.1038/s41572-022-00398-y
Torre LA, Siegel RL, Islami F, Bray F, Jemal A. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers. Clin Gastroenterol Hepatol. 2018;16(3):427‐437. doi:10.1016/j.cgh.2017.08.017
Bustos BI, Perez‐Palma E, Buch S, et al. Variants in ABCG8 and TRAF3 genes confer risk for gallstone disease in admixed Latinos with Mapuche Native American ancestry. Sci Rep. 2019;9(1):772. doi:10.1038/s41598-018-35852-z
Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5(2):93‐102. doi:10.5114/ceh.2019.85166
Son SY, Song JH, Shin HJ, Hur H, Han SU. Prevention of gallstones after bariatric surgery using ursodeoxycholic acid: a narrative review of literatures. J Metab Bariatr Surg. 2022;11(2):30‐38. doi:10.17476/jmbs.2022.11.2.30
Amorim‐Cruz F, Santos‐Sousa H, Ribeiro M, et al. Risk and prophylactic management of gallstone disease in bariatric surgery: a systematic review and a Bayesian meta‐analysis. J Gastrointest Surg. 2023;27(2):433‐448. doi:10.1007/s11605-022-05567-8
Belgau I, Johnsen G, Graeslie H, et al. Frequency of cholelithiasis in need of surgical or endoscopic treatment a decade or more after Roux‐en‐Y gastric bypass. Surg Endosc. 2023;37(2):1349‐1356. doi:10.1007/s00464-022-09676-y
Joshi AD, Andersson C, Buch S, et al. Four susceptibility loci for gallstone disease identified in a meta‐analysis of genome‐wide association studies. Gastroenterology. 2016;151(2):351‐363. e28. doi:10.1053/j.gastro.2016.04.007
Ferkingstad E, Oddsson A, Gretarsdottir S, et al. Genome‐wide association meta‐analysis yields 20 loci associated with gallstone disease. Nat Commun. 2018;9(1):5101. doi:10.1038/s41467-018-07460-y

Auteurs

Lukasz Krupa (L)

Department of Gastroenterology and Hepatology with Internal Disease Unit, Teaching Hospital No 1 in Rzeszów, Rzeszów, Poland.
Medical Department, University of Rzeszów, Rzeszów, Poland.

Piotr Kalinowski (P)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Joanna Ligocka (J)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Marc Dauer (M)

Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.

Krzysztof Jankowski (K)

Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland.
Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland.

Jolanta Gozdowska (J)

Department of Transplantation Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland.

Beata Kruk (B)

Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Piotr Milkiewicz (P)

Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

Krzysztof Zieniewicz (K)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Marek Krawczyk (M)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Susanne N Weber (SN)

Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.

Frank Lammert (F)

Hannover Medical School (MHH), Hannover, Germany.

Marcin Krawczyk (M)

Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.
Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Classifications MeSH